Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | C7R.CD30.CAR-EBVS T-cells |
| Synonyms | |
| Therapy Description |
Limited information is currently available on C7R.CD30.CAR-EBVS T-cells, putative allogeneic T-cells that have been engineered to express constitutive IL7R (C7R) and a chimeric antigen receptor (CAR) targeting TNFRSF8 (CD30) (Feb 2024). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| C7R.CD30.CAR-EBVS T-cells | C7R.CD30.CAR-EBVST cells | CD30 (TNFRSF8) Immune Cell Therapy 5 | Limited information is currently available on C7R.CD30.CAR-EBVS T-cells, putative allogeneic T-cells that have been engineered to express constitutive IL7R (C7R) and a chimeric antigen receptor (CAR) targeting TNFRSF8 (CD30) (Feb 2024). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06176690 | Phase I | C7R.CD30.CAR-EBVS T-cells | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (CABAL2) | Recruiting | USA | 0 |